Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer

MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we conducted a toxicity study using the zebrafish and rodent model. MM-129 was also assessed for pharmacokinetics features through an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanowicz, Justyna Magdalena, Kalaska, Bartlomiej, Pawlak, Krystyna, Sieklucka, Beata, Miklosz, Joanna, Mojzych, Mariusz, Pawlak, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400941/
https://www.ncbi.nlm.nih.gov/pubmed/34452183
http://dx.doi.org/10.3390/pharmaceutics13081222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400941/
https://www.ncbi.nlm.nih.gov/pubmed/34452183
http://dx.doi.org/10.3390/pharmaceutics13081222

Ejemplares similares